Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia

References

• Kirsch M, Schackert G, Black PM. Metastasis and angiogen-esis. Cancer Treat Res 2004;117:285–304.
   PubMedGoogle Scholar
• Kay NE, Bone ND, Howell KH, Hansan CA, Jelinek DF. B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia 2002;16:911–919.
   Google Scholar
• Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94(11):3717–3721.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Giles F, Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syn-dromes. Leuk Lymphoma 2003;44:213–222.
   Google Scholar
• Aref S, Mabed M, Sakrana M. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor in adult AML: Relationship to disease characteristics. Hematology 2002;7:273–279.
   Google Scholar
• Gu J, Gadonski G, Wang J, Makey I, Adair T. Exercise increases endostatin in circulation of health volunteers. BMC Physiol 2004;4:2–5.
   Google Scholar
• Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, Cuneo A, Ribatti D, Digiesi G. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. Eur J Haematol 2004;73:36–42.
   PubMed Web of Science ®Google Scholar
• Yetgin S, Yenicesu I, Cetin M, Tuncer M. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma 2001;42(1-2):83–88.
   PubMed Web of Science ®Google Scholar
• Faderl S, Do KA, Johnson MM, Keating M, O’brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 2005;106:4303–4307.
   Google Scholar
• Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae S, Lee KS, Lee BK. Clinical implication of angiogenic factors in patients with: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma 2005;46:885–891.
   Google Scholar
• Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728–733.
   PubMed Web of Science ®Google Scholar
• Perez-Atayde A, Sallan S, Tedrow U, Connors S, Allred E, Folkmon J. Spectrum of tumor angiogenesis in the bore marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815–825.
   Google Scholar
• Athanassiadou F, Catriu D, Papageorgioiu T, Fidani S. Effect of GM-CSF on TNF-a, IL-3 and IL-7 levels in vitro and in vivo in children with acute lymphoblastic leukemia. J Hellenic Soc Hematol 1999;2:139.
   Google Scholar
• Schulz U, Munker R, Ertl B, Holler E, Kolb HJ. Different types of human leukemias express the message for TNF-ct and IL-10. Eur J Med Res 2001;6(8):359.
   PubMed Web of Science ®Google Scholar
• de Bont ES, Kimpen JL, Tamminga RY, Niemarkt AE, de Leij LH, Kamps WA. Intrinsic capacity of monocytes to produce cytokines ex vivo in patients with acute lymphoblastic leukaemia. Cytokine 2000;12:1723–1726.
   PubMed Web of Science ®Google Scholar
• Pituch-Noworolska A, Gawlicka M, Wotoszyn M, Balwierz W, Strojny W, Zembala M. Tumour necrosis factor alpha (TNF alpha) and leukaemic cells: Secretion and response. Clin Lab Haematol 1998;20:231–238.
   Google Scholar
• Chandrasekar N, Jasti S, Alfred-Yung WK, Ali-Osman F, Dinh DH, Olivero WC, Gujrati M, Kyritsis AP, Nicolson GL, Rao JS, Mohanam S. Modulation of endothelial cell morphogen-esis in vitro by MMP-9 during glial-endothelial cell inter-actions. Clin Exp Metastasis 2000;18: 337–342.
   Google Scholar
• Lin U, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 2002;117:835–841.
   PubMed Web of Science ®Google Scholar
• Hendrix MJ, Seftor EA, Grogan TM, Seftor RE, Hersh EM, Boyse EA, Liotta LA, Stetler-Stevenson W, Ray CG. Expression of type IV collagenase correlates with the invasion of human lymphoblastoid cell lines and pathogenesis in SCID mice. Mol Cell Probes 1992;6:59–65.
   Google Scholar
• Ivanoff A, Ivanoff J, Hultenby K, Sundqvist KG. Infiltrative capacity of T leukemia cell lines: A distinct functional property coupled to expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-I). Clin Exp Metastasis 1999;17:695–711.
   PubMed Web of Science ®Google Scholar
• Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL. bFGF expression in human bone marrow and peripheral blood cells. Blood 1993;81:631–638.
   Google Scholar
• Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM. Platelet: Trans-porter of vascular endothelial growth factor. Clin Cancer Res 1997;3(12 Pt 1):2187–2190.
   Google Scholar
• Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M, Toh CH. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000;96:3181–3187.
   Google Scholar
• Molica S, Santoro R, Dattilo A, Levato D, Muleo G. VEGF isoforms 121 and 165 are expressed on B-chronic lymphocytic leukemia cells. Hematologica 2000;85: 1106–1108.
   PubMed Web of Science ®Google Scholar
• Peterson L, Kini AR. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 2001;97:2529.
   PubMed Web of Science ®Google Scholar
• Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C, Guarini A, di Celle PF, Fierro MT. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease. Blood 1990;76:393–400.
   Google Scholar
• Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm 2003;12:167–171.
   Google Scholar
• Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002;16:911–919.
   PubMed Web of Science ®Google Scholar
• Kamiguti AS, Lee ES, Till KJ, Harris RJ, Glenn MA, Lin K, Chen HJ, Zuzel M, Cawley JC. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocy-tic leukaemia. Br J Haematol 2004;125: 128–140.
   PubMed Web of Science ®Google Scholar
• Bauvois B, Dumont J, Kolb JP, et al. Production of matrix metalloprteinase-9 in early stage B-chronic lymphocytic leukemia. Leukemia 2002;16:791–798.
   PubMedGoogle Scholar
• Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, Peschel C, Decker T. Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004; 18:1964–1970.
   Google Scholar
• Gora-Tybor J, Blonski JZ, Robak T. Circulating VEGF and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytok Netw 2005;16:141–146.
   Google Scholar
• Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O’Brien S, Albitar M. The clinical significance of TNF-ct plasma level in patients having chronic lymphocytic leukemia. Blood 2002;100:1215–1219.
   Google Scholar